The results of the AbATE clinical trial to slow the progression of type 1 diabetes have been trickling out at conferences and talks for a while now,…
Category: Science
Dr. Ferber wants to take a patient’s own liver cells, turn them into beta cells in the lab, and then put them back in the patient just like an islet cell transplant. Because the starting cells are the patient’s own cells, important protein markers on the cells would “match” what the patient’s immune system expects, and the cells would in theory not induce an immune reaction like an organ transplant would.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded that presently available data does not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based diabetes therapies.
In anticipation of stable, liquid glucagon, one of the newest entrants into the insulin pump space, Tandem Diabetes Care has jumped ahead of the crowd and created a two-chamber infusion pump capable of holding and injecting both insulin and a secondary hormone, which they expect will be glucagon. This tandem Tandem pump is already being tested in Dr. Ed Damiano's clinical trial of a dual-hormone bionic pancreas.
Great strides have been made recently in predicting who is most likely to develop type 1 diabetes, allowing researchers to identify the disease at the earliest stages of development and potentially intervene to preserve beta cell function at a much earlier stage and ultimately prevent onset of symptomatic diabetes.
JDRF has announced a two partnerships to support the development soluble glucagon formulations—an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D).
Five adults in the UK with type 1 diabetes have used an artificial pancreas in their homes without medical supervision. This step offers real hope for a future where people with type 1 diabetes no longer have to monitor blood glucose levels, and where they have a better chance of living a long and healthy life.
This month the American Diabetes Association published the e-book edition of Targeting a Cure for Type 1 Diabetes: How Long Will We Have to Wait?…
Biodel has announced plans to submit a New Drug Application (NDA) to the FDA in 2015 for a novel glucagon rescue device to treat severe hypoglycemia.
Having previously signed a long-term commercial supply agreement for bulk glucagon, Biodel expects to select a final formulation of its novel glucagon therapy...
According to a series of study results being published in a special issue of Diabetes Care youth with type 2 diabetes experience a more rapid progression of co-morbidities far more aggressive than what is typically seen in adults, even when they receive the best currently available treatment and close monitoring of their condition.